Prurigo nodularis
Also known as: Nodular prurigo, Chronic nodular prurigo, Prurigo nodularis of Hyde
Prurigo nodularis (PN) is a chronic inflammatory dermatosis characterised by intensely pruritic nodules, persistent excoriation, and secondary sleep disturbance, frequently resulting in significant psychosocial impairment. General practitioner or dermatologist assessment is required to confirm diagnosis and exclude systemic aetiologies of pruritus. Current clinical data support dupilumab and nemolizumab for pruritus reduction and lesional clearance; conversely, evidence for ruxolitinib gel remains preliminary due to limited trial cohorts. Mechanistic data regarding vitamin D do not currently substantiate clinical supplementation efficacy. There are no assessable outcomes for abrocitinib in the present evidence, and the cited literature does not evaluate acupuncture or Chinese herbal medicine for PN. Traditional Chinese Medicine pattern differentiation may provide supportive care, provided it does not delay conventional medical intervention or imply unsubstantiated therapeutic outcomes.
Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.
Lifestyle & Diet
- •Utilise brief, lukewarm showers and apply fragrance-free, non-irritating emollients.
- •Maintain short fingernails and utilise soft textiles or clinician-recommended occlusive dressings to mitigate excoriation-induced trauma.
- •Maintain a cool ambient temperature in the sleeping environment and monitor pruritus intensity and sleep quality to facilitate clinical assessment.
- •Maintain a nutritionally balanced diet; avoid high-dose vitamin D supplementation or restrictive dietary regimens based on preliminary mechanistic research.
Cautions & Contraindications
- •Do not replace or delay dermatological assessment or prescribed treatment with acupuncture or herbal medicine. The supplied evidence supports selected targeted medicines, not TCM efficacy.[]
- •Do not infer that vitamin D supplements treat PN from VDR–AADAC laboratory findings. Supplementation decisions require conventional assessment; patient benefit and a PN supplementation regimen were not established.[]
- •Avoid needling through nodules, excoriations, infected skin or ulceration. Screen for bleeding risk, impaired healing and immunosuppression. These are general procedural precautions; the supplied studies did not evaluate acupuncture safety.[,]
- •Do not assume herbs can safely be combined with biologics, JAK inhibitors or other systemic treatment: undertake medicine reconciliation and pharmacist or prescriber review. The supplied trials do not establish herbal interaction safety, and longer-term targeted-treatment safety remains incompletely characterised.[,]
When to reassess or seek care again
Record baseline weekly average worst itch on a 0–10 scale, nights of disrupted sleep, lesion photographs with consent, and daily-function impact. Review any adjunctive trial within 2–4 weeks, including adverse effects and medicine changes. Stop or revise adjunctive care if there is no agreed meaningful benefit, and seek dermatology review for worsening lesions, persistent severe itch or ongoing sleep impairment. A four-point itch reduction is a trial outcome in source 3, not an established expectation for TCM. New infection signs or other red flags require immediate escalation rather than waiting for review.
Explore more diseases
Sources & Further Reading
Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.
- FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
- American journal of therapeutics · 2026
- Frontiers in medicine · 2026
- Dermatology and therapy · 2026
Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.
